Cadonilimab
Cadonilimab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
227 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 3 | 28 | 3 | — | 5 | 35 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 5 | 20 | 2 | — | 3 | 27 |
| Uterine cervical neoplasms | D002583 | — | — | 2 | 14 | 2 | — | 6 | 24 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 17 | 2 | — | — | 19 |
| Colorectal neoplasms | D015179 | — | — | 2 | 16 | 1 | — | 1 | 18 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 14 | 2 | — | 1 | 17 |
| Adenocarcinoma | D000230 | — | — | 3 | 11 | 3 | — | — | 15 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 11 | 2 | — | 2 | 14 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 11 | 1 | — | — | 13 |
| Recurrence | D012008 | — | — | 1 | 5 | 2 | — | 2 | 9 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 11 | 14 | — | — | — | 18 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | 12 | — | — | 1 | 13 |
| Squamous cell carcinoma | D002294 | — | — | — | 10 | — | — | 1 | 11 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 7 | — | — | — | 7 |
| Melanoma | D008545 | — | — | 3 | 3 | — | — | 1 | 6 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 5 | — | — | 1 | 6 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 6 | — | — | — | 6 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 5 | — | — | — | 6 |
| Small cell lung carcinoma | D055752 | — | — | 1 | 5 | — | — | — | 5 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | 4 | — | — | — | 5 |
Show 35 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cryosurgery | D003452 | — | — | — | — | — | — | 1 | 1 |
| Small cell carcinoma | D018288 | — | — | — | — | — | — | 1 | 1 |
| Neuroendocrine carcinoma | D018278 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cadonilimab |
| INN | cadonilimab |
| Description | Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody developed to treat a variety of solid cancer types. In June 2022 it was approved in China "for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy".
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594456 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 6FYG1DS4NW (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 958 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
42 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use